Skip to content
AnalystLens

Idex Annual Report, Year Ended Dec 31, 2017

Filing Date
Filed February 22, 2018
Period End
December 31, 2017
Security
IEX
One revenue dollarkept$0.15
In the record · 2016–202610-K1110-Q338-K119

IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Mar ’17Mar ’17
  2. Material agreement8-K · Apr ’20Apr ’20
  3. Leadership change8-K · Sep ’22Sep ’22
  4. Material agreement8-K · Sep ’26Sep ’26

Summary

Summary of the 10-K filed February 22, 2018. Cited figures are marked; the original filing is the authoritative source.

IDEX Corporation's 2017 Form 10-K reports net sales of $2,287,312 thousanda ($2.29 billion), up 8% from $2,113,043 thousand in 2016, with organic sales up 6% and acquisitions/divestitures adding 2%.

Operating income rose 22% to $502,556 thousandb, and operating margin was 22.0%, up 250 basis points. Net income increased 24% to $337,257 thousand, and diluted EPS was $4.36, compared with $3.53 in 2016. Adjusted EPS, which excludes restructuring, divestiture gains and losses, and a 2016 pension settlement, was $4.31, up from $3.75.

Adjusted EBITDA was $583,560 thousandc, flat with 2016 in margin terms at 25.5%. The company operates three reportable segments: Fluid & Metering Technologies (38% of 2017 sales), Health & Science Technologies (36%), and Fire & Safety/Diversified Products (26%). Roughly 49% of 2017 sales were to customers outside the U.S. Cash flow from operations was $432.8 million, and capital expenditures were $43.9 million.

Total borrowings declined to $862.2 milliond from $1,020.9 million, and shareholders' equity rose to $1,886.5 million. Management projects approximately 5% organic revenue growth and full-year 2018 EPS of $4.90 to $5.10.

The 2017 results include a $9.3 million gain on the Faure Herman divestiture, $8.5 million of restructuring expense, and a provisional net $0.1 million tax benefit from the Tax Cuts and Jobs Act, which included a $30.3 million transition tax expense and a $40.6 million deferred tax benefit. Goodwill and intangibles totaled $1,704.2 million and $414.7 million, respectively, against $3,399.6 million of total assets.

Key Highlights

  1. Net sales of $2.29 billion, up 8%, with organic growth of 6% and acquisitions/divestitures adding 2%
  2. Operating income of $502.6 million, up 22%; operating margin of 22.0%, up 250 basis points
  3. Diluted EPS of $4.36, up from $3.53; adjusted EPS of $4.31, up from $3.75
  4. Cash flow from operations of $432.8 million; cash and equivalents of $376.0 million at year-end
  5. Total borrowings reduced to $862.2 million from $1,020.9 million; shareholders' equity rose to $1,886.5 million
  6. 2018 outlook: approximately 5% organic revenue growth and full-year EPS of $4.90 to $5.10
  7. Tax Cuts and Jobs Act produced a net $0.1 million provisional tax benefit, comprising a $40.6 million deferred tax benefit and $30.3 million transition tax expense

Follow one dollar

Of each $1.00 of revenue in FY2017, Idex kept $0.15.

  1. Revenue$2.29B100.0%
  2. Cost of revenue−$1.26B55.1%
  3. Gross profit$1.03B44.9%
  4. Operating costs−$524.1M22.9%
  5. Operating income$502.6M22.0%
  6. Interest, other & tax−$165.3M7.2%
  7. Net income$337.3M14.7%
Computed from 10-KFY2017filed February 22, 2018Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

FY2017 against FY2016

Line itemFY2017FY2016Change
Revenue$2.29B$2.11B+8.2%
Cost of Revenue$1.26B$1.18B+6.6%
Gross Profit$1.03B$930.77M+10.3%
R&D Expenses$42.40M$39.40M+7.6%
SG&A Expenses$524.94M$492.40M+6.6%
Operating Income$502.56M$412.40M+21.9%
Interest Expense$44.89M$45.62M−1.6%
Net Income$337.26M$271.11M+24.4%
EPS (Basic)$4.41$3.57+23.5%
EPS (Diluted)$4.36$3.53+23.5%
Shares Outstanding (Basic)76.23M75.80M+0.6%
Shares Outstanding (Diluted)77.33M76.76M+0.7%

Frequently Asked Questions

  1. What drove the increase in operating income in 2017?

    Operating income rose to $502.6 million from $412.4 million, primarily due to a $9.3 million gain on the Faure Herman divestiture compared with a $22.3 million net loss on four divestitures in 2016, higher sales volume, and the absence of $14.7 million of inventory step-up charges from 2016 acquisitions. These gains were partially offset by higher restructuring costs and higher SG&A from variable and share-based compensation.

  2. How concentrated is IDEX's customer base and where are its sales generated?

    No customer accounted for more than two percent of 2017 net sales. Sales were 51% domestic and 49% international, with the Health & Science Technologies segment deriving about 55% of its sales outside the U.S.

  3. What is the company's acquisition strategy and balance sheet exposure?

    IDEX pursues acquisitions as a core growth strategy. In 2017 it acquired thinXXS for $38.2 million in cash plus $1.2 million of assumed debt. Goodwill of $1,704.2 million and intangible assets of $414.7 million together represent a significant portion of total assets, creating impairment risk if performance falls short of forecasts.

  4. What are the key financing arrangements and covenants?

    Total borrowings were $862.2 million at December 31, 2017, including $750 million of fixed-rate senior notes and $10.7 million drawn on a $700 million revolving facility expiring in June 2020. The company was in compliance with its covenants, with an interest coverage ratio of 13.64 to 1 against a 3.0 to 1 minimum and a leverage ratio of 1.45 to 1 against a 3.50 to 1 maximum.

  5. How did the Tax Act affect IDEX's 2017 results?

    The company recorded a net $0.1 million tax benefit, which combined a $40.6 million provisional deferred tax benefit from remeasuring deferred tax balances, $30.3 million of provisional transition tax expense on deemed repatriated foreign earnings, and $10.2 million of additional expense from removing permanent reinvestment assertions for certain subsidiaries. The company expects to finalize these amounts during 2018.